365 Days of Caring: 13 Ways Johnson & Johnson Helped Progress Health for Humanity in 2018
COVID-19 Update: Your Latest Questions About Johnson & Johnson's Investigational Vaccine Candidate AnsweredDid you like reading this story? Click the heart to show your love.
The COVID-19 Data Plan: 3 Innovative Ways Johnson & Johnson Is Using Data Science to Fight the PandemicDid you like reading this story? Click the heart to show your love.
A Message from Chairman and CEO Alex Gorsky About Johnson & Johnson's Investigational COVID-19 Vaccine CandidateDid you like reading this message? Click the heart to show your love.
ealth should be accessible to all.
And yet every day people and communities around the globe face complex diseases and environmental challenges.
Which is why, as the world’s largest and most broadly based healthcare company, Johnson & Johnson is committed to using its reach and size to help improve the health of people around the world and the environment in which they live.
From efforts to help fight and prevent disease to the development of more sustainable products, the company’s newly released 2018 Health for Humanity Report details the progress the company made last year toward meeting the Health for Humanity Goals it has pledged to achieve by 2020, as well as the U.N.’s 2030 Sustainable Development Goals.
“At Johnson & Johnson, we know that changing the trajectory of health of humanity requires dedication and commitment on many fronts,” says tenet of our values as a company.”, Chairman and CEO, Johnson & Johnson. "We’re proud to share this year’s Health for Humanity Report, which details the progress we’ve made in improving our environmental, social and governance practices—and we’re committed to finding even more ways to create a healthier society. It’s not just part of our business model, it’s a fundamental
Month by month, effort by effort, learn about just some of the ways Johnson & Johnson worked last year to make the world a healthier place—and ensure it becomes even healthier for each generation to come.
When you receive a cancer diagnosis, it’s natural to want to go online to get more information—and easy to get overwhelmed. That’s why Janssen Oncology, part of the Janssen Pharmaceutical Companies of Johnson & Johnson, launched Cancer.com: a one-stop digital destination that's tailored to patients and their caregivers based on several different types of cancer and where they are in their journey. The goal? Help guide them through many of the decisions they’ll have to make when faced with the disease.Read More
The Johnson & Johnson Institute on Wheels Hits the Road
With a population of over 1.3 billion—and growing—it’s not always easy for many people in India to get access to the medical care they need. In fact, there are only six physicians and 13 nurses for every 10,000 people in the country.
The mobile Johnson & Johnson Institute on Wheels, which got rolling last March, is helping to train healthcare professionals—doctors, nurses and paramedical staff—over the next five years in service of providing better outcomes for patients across the country. So far, it has reached 73 towns and 113 medical institutions, training over 10,500 healthcare professionals.Read More
A Project to Help Develop Better Treatments for Babies Is Born
In May 2018, Johnson & Johnson joined forces with academic and industry partners to form a European network called conect4children that’s helping facilitate pediatric clinical trials with the hope of developing better treatments for babies, kids and young people.Read More
JLABS @ NYC Opens Its Doors
In the seven years since its inception, Johnson & Johnson Innovation, JLABS— an incubator that helps healthcare entrepreneurs bring their innovations to life by providing mentoring and resources like lab space—has supported more than 500 start-ups at its nine locations around the world, from California to Belgium. In June 2018, JLABS @ NYC, which will focus on biotech, pharmaceutical, medical device and consumer health innovations, was added to the roster.
And one healthcare challenge in particular got an R&D boost this month, too, when the Janssen Pharmaceutical Companies of Johnson & Johnson initiated a Phase 1b/2 clinical development program as part of a collaboration with Legend Biotech USA to develop a potential chimeric antigen receptor T cell therapy (CAR-T) for multiple myeloma, an incurable blood cancer.Read More
Promising Early Results Come in for Janssen's HIV Vaccine
In 2017, Johnson & Johnson and global partners launched the Imbokodo study to see if a new preventive vaccine regimen might be able to help reduce HIV infections in women in sub-Saharan Africa—a population at higher risk of contracting the disease. In July 2018, early stage data from the APPROACH study was published in The Lancet, suggesting that the regimen induced a robust immune response to the virus in humans. Just a few weeks later, the first long-term immune response results from APPROACH were presented at the AIDS 2018 conference.Read More
A Potentially Lifesaving Mental Health Program Launches in Rwanda
Another important company commitment: providing resources to those living with mental illness. Due in part to a lack of local support, up to 85% of people with serious mental disorders living in low- and middle-income countries haven’t received treatment for their conditions, according to the World Health Organization (WHO).
To help address this unmet need in Rwanda, Johnson & Johnson announced a partnership in August with the Government of Rwanda and other organizations to improve access to quality mental healthcare in the country, including training community healthcare workers—with hopes to eventually expand the program throughout sub-Saharan Africa. One focus of the partnership: creating a platform for patients with schizophrenia to have access to treatment with long-acting injectables, which may be particularly helpful to those who don't have frequent access to medical care.Read More
The Health for All Alliance Is Formed
At the 2018 Global Citizen Festival in New York City, Johnson & Johnson announced that it was joining the WHO, government partners and other organizations to create the Health for All Alliance, which will work to ensure healthcare workers worldwide can access the skills and digital tools they need to help save lives.
And through a collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) and The Jenner Institute at the University of Oxford, Janssen Vaccines & Prevention B.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced it will work on developing novel vaccines to protect against three potential global threats for which no vaccines currently exist: the Middle East Respiratory Syndrome (MERS) virus, the brain-damaging Nipah virus, and the Lassa virus, which causes hemorrhagic fever.Read More
The Johnson & Johnson Nurses Innovate QuickFire Challenge Is Announced
The company’s inaugural Nurses Innovate QuickFire Challenge invited nurses to submit concepts for life-changing devices, health technologies, protocols or treatment approaches that have the potential to transform human health. During National Nurses Week in May 2019, two awardees were announced, with each receiving $50,000 in grants, plus ongoing mentoring and coaching from Johnson & Johnson Innovation, JLABS, to help bring their solutions to life.
Johnson & Johnson made an important commitment to the planet in October, too. Plastic waste is one of the most urgent environmental issues of our time, which is why Johnson & Johnson Consumer signed the New Plastics Economy Global Commitment—alongside more than 250 other companies, governments and NGOs—pledging to use more recycled materials in its packaging, reduce reliance on single-use packages, and ensure that 100% of its plastic packaging be reusable, recyclable or compostable by 2025.Read More
UNICEF Receives a $10 Million Pledge
Johnson & Johnson has had a strong global partnership with UNICEF for over 30 years. In November 2018, the company strengthened that bond through a $10 million pledge to support health workers in delivering care to newborns, children and mothers around the world, including among Indigenous communities in Vietnam and the Philippines.Read More
A Treatment for Intestinal Worm Infections Helps Kids Around the Globe
Soil-transmitted helminths (STH), also known as intestinal worm infections, affect approximately 1.5 billion people worldwide. Kids are particularly vulnerable to STH, which can often lead to malnutrition and even impaired cognitive development. So in December, Janssen submitted a prequalification dossier to the WHO for a pediatric formulation of a worm-fighting medication that can either be chewed or mixed with a small amount of water to form a soft mass that's easier for very young children to swallow.
In April 2019, the WHO prequalified the formulation, which will support the introduction of this medication in STH treatment programs in high-burden countries. Johnson & Johnson will soon begin distributing it as part of the 200 million doses of the treatment it’s committed to donating around the world annually.Read More